Notice: This company has been marked as potentially delisted and may not be actively trading. Fusion Pharmaceuticals (FUSN) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Fusion Finance Ltd (FUSN)November 5, 2024 | investing.comJapan start-up aims to launch world's first steady-state fusion reactor in 2034August 31, 2024 | msn.comFusion Pharma (FUSN) Earnings Dates & ReportsAugust 7, 2024 | investing.comAvidity Partners Management LP Increases Holdings in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Avidity Partners Management LP raised its holdings in shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,500,328 sharJune 11, 2024 | marketbeat.comSuperstring Capital Management LP Takes $440,000 Position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Superstring Capital Management LP bought a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 45,801 shares of the company's stock, valued aJune 10, 2024 | marketbeat.comAcquisition of Fusion Pharmaceuticals CompletedJune 4, 2024 | prnewswire.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Average Recommendation of "Hold" by AnalystsShares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the fourteen ratings firms that are presently covering the company, MarketBeat reports. Thirteen investment analysts have rated the stock with a hold rating and one haJune 4, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Sets New 12-Month High at $21.60Fusion Pharmaceuticals (NASDAQ:FUSN) Sets New 52-Week High at $21.60May 31, 2024 | marketbeat.comFusion Pharmaceuticals Receives Final Court Order Approving ArrangementMay 31, 2024 | prnewswire.comFusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume IncreaseFusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume IncreaseMay 30, 2024 | marketbeat.comFusion Pharmaceuticals Shareholders Approve Acquisition by AstraZenecaMay 29, 2024 | prnewswire.comJump Financial LLC Invests $828,000 in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Jump Financial LLC acquired a new stake in shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 86,199 shares of the company's stock, valued at approximately $828,000. Jump Financial LLC owneMay 20, 2024 | marketbeat.comFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate CancerMay 9, 2024 | prnewswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMay 9, 2024 | businesswire.comQ2 2024 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Boosted by William BlairFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Investment analysts at William Blair lifted their Q2 2024 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a research note issued on Tuesday, May 7th. William Blair analyst A. Hsieh now forecasts that the company will postMay 9, 2024 | marketbeat.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | investorplace.comFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program UpdatesMay 7, 2024 | prnewswire.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Sees Significant Drop in Short InterestFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 4,860,000 shares, a decline of 6.5% from the March 31st total of 5,200,000 shares. Based on an average daily trading volume, of 2,140,000 shares, the days-to-cover ratio is currently 2.3 days.May 1, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Hits New 12-Month High at $21.56Fusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 52-Week High at $21.56May 1, 2024 | marketbeat.comJennison Associates LLC Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Jennison Associates LLC purchased a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 301,020 shares of the company's stock, valued at approximatApril 27, 2024 | marketbeat.comTop 4 Health Care Stocks That May Plunge This MonthApril 26, 2024 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)April 26, 2024 | markets.businessinsider.comFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim OrderApril 25, 2024 | prnewswire.comFusion Pharmaceuticals Inc Ordinary SharesApril 19, 2024 | morningstar.comFederated Hermes Inc. Acquires 202,364 Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Federated Hermes Inc. lifted its holdings in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,886,153 shares of the company's stockApril 19, 2024 | marketbeat.comFusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should KnowApril 17, 2024 | finance.yahoo.comTD Cowen Downgrades Fusion Pharmaceuticals (FUSN)April 17, 2024 | msn.comHealthInvest Partners AB Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)HealthInvest Partners AB acquired a new position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 125,000 shares of the company's stock, valued at approximately $1,April 16, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Earns "Hold" Rating from TD CowenTD Cowen restated a "hold" rating on shares of Fusion Pharmaceuticals in a research report on Tuesday.April 16, 2024 | marketbeat.comLeerink Partnrs Analysts Cut Earnings Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Analysts at Leerink Partnrs cut their Q1 2024 earnings estimates for Fusion Pharmaceuticals in a note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.37)April 12, 2024 | marketbeat.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the companyApril 11, 2024 | finance.yahoo.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 9, 2024 | finance.yahoo.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 9, 2024 | prnewswire.comFusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 12-Month High at $21.55Fusion Pharmaceuticals (NASDAQ:FUSN) Hits New 1-Year High at $21.55April 4, 2024 | marketbeat.comGenmab Buys ProfoundBio for $1.8B to Boost Oncology PortfolioApril 3, 2024 | msn.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Short Interest Down 8.3% in MarchFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 7,920,000 shares, a decrease of 8.3% from the February 29th total of 8,640,000 shares. Based on an average daily volume of 2,210,000 shares, the short-interest ratio is presently 3.6 days.April 2, 2024 | marketbeat.comWhat Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for InvestorsMarch 28, 2024 | msn.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSNMarch 26, 2024 | prnewswire.comFusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 1-Year High at $21.32Fusion Pharmaceuticals (NASDAQ:FUSN) Sets New 52-Week High at $21.32March 25, 2024 | marketbeat.comYarbrough Capital LLC Acquires Shares of 76,872 Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)Yarbrough Capital LLC acquired a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 76,872 shares of the company's stock, valued at approximately $739,0March 24, 2024 | marketbeat.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Expected to Earn FY2023 Earnings of ($1.36) Per ShareFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Equities researchers at Bloom Burton lifted their FY2023 earnings per share (EPS) estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 20th. Bloom Burton analyst D. MartinMarch 22, 2024 | marketbeat.comFY2026 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Raised by AnalystFusion Pharmaceuticals Inc. (NASDAQ:FUSN - Free Report) - Investment analysts at Wedbush increased their FY2026 earnings estimates for shares of Fusion Pharmaceuticals in a note issued to investors on Tuesday, March 19th. Wedbush analyst D. Nierengarten now expects that the company will post earnMarch 21, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Downgraded by Bloom BurtonBloom Burton downgraded Fusion Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday.March 21, 2024 | marketbeat.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023March 20, 2024 | msn.comFusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market DynamicsMarch 20, 2024 | markets.businessinsider.comKuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law FirmMarch 20, 2024 | stockhouse.comFusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program UpdatesMarch 20, 2024 | finance.yahoo.comUnveiling 11 Analyst Insights On Fusion PharmaceuticalsMarch 20, 2024 | markets.businessinsider.comB. Riley Reiterates "Neutral" Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)B. Riley reissued a "neutral" rating and issued a $23.00 price objective (up previously from $13.00) on shares of Fusion Pharmaceuticals in a research report on Wednesday.March 20, 2024 | marketbeat.comFusion Pharmaceuticals (NASDAQ:FUSN) Downgraded to "Market Perform" at Leerink PartnrsLeerink Partnrs cut Fusion Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Tuesday.March 20, 2024 | marketbeat.com Get Fusion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter. Email Address 📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%. Take these 4 steps to protect your retirement here >>> FUSN Media Mentions By Week FUSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FUSN News Sentiment▼0.000.49▲Average Medical News Sentiment FUSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FUSN Articles This Week▼02▲FUSN Articles Average Week Get Fusion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MeiraGTx News Y-mAbs Therapeutics News Halozyme Therapeutics News Krystal Biotech News ADMA Biologics News Arcellx News CRISPR Therapeutics News Immunovant News ImmunityBio News Denali Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FUSN) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
